

CITATION REPORT

List of articles citing

Biological Characterization of SB3, a Trastuzumab Biosimilar, and the Influence of Changes in Reference Product Characteristics on the Similarity Assessment

DOI: 10.1007/s40259-019-00362-5
BioDrugs, 2019, 33, 411-422.

Source: <https://exaly.com/paper-pdf/72943941/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
15	Assessment of the Molecular Mechanism of Action of SB3, a Trastuzumab Biosimilar. <i>BioDrugs</i> , 2019 , 33, 661-671	7.9	5
14	Reporting of quality attributes in scientific publications presenting biosimilarity assessments of (intended) biosimilars: a systematic literature review. <i>European Journal of Pharmaceutical Sciences</i> , 2020 , 154, 105501	5.1	3
13	Biologic Drug Quality Assurance to Optimize HER2 + Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3. <i>Targeted Oncology</i> , 2020 , 15, 467-475	5	3
12	Demonstrating Analytical Similarity of Trastuzumab Biosimilar HLX02 to Herceptin with a Panel of Sensitive and Orthogonal Methods Including a Novel FcR11a Affinity Chromatography Technology. <i>BioDrugs</i> , 2020 , 34, 363-379	7.9	12
11	Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars. <i>BioDrugs</i> , 2020 , 34, 225-233	7.9	4
10	The Path Towards a Tailored Clinical Biosimilar Development. <i>BioDrugs</i> , 2020 , 34, 297-306	7.9	12
9	Challenges for biosimilars: focus on rheumatoid arthritis. <i>Critical Reviews in Biotechnology</i> , 2021 , 41, 1219-1233	4.3	4
8	Multiple-parallel-protease digestion coupled with high-resolution mass spectrometry: An approach towards comprehensive peptide mapping of therapeutic mAbs. <i>Journal of Proteomics</i> , 2021 , 232, 104053-9	3.9	2
7	Biyobenzer Tabir. <i>Beykent Üniversitesi Fen Ve Mühendislik Bilimleri Dergisi</i> ,		
6	Maintaining standards for biosimilar monoclonal antibodies. <i>Nature Biotechnology</i> , 2021 , 39, 276-280	44.5	5
5	New Quality-Range-Setting Method Based on Between- and Within-Batch Variability for Biosimilarity Assessment. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	
4	Comparability of Biologics: Global Principles, Evidentiary Consistency and Unrealized Reliance. <i>BioDrugs</i> , 2021 , 35, 379-387	7.9	1
3	Need for a risk-based control strategy for managing glycosylation profile for biosimilar products. <i>Expert Opinion on Biological Therapy</i> , 2021 , 1-9	5.4	1
2	Biosimilars in an era of rising oncology treatment options. <i>Future Oncology</i> , 2021 , 17, 3881-3892	3.6	0
1	Drifts in N-Linked Glycosylation Result in ADCC Potency Variation of Perjeta from August 2020 to October 2021 in China.. <i>BioMed Research International</i> , 2022 , 2022, 7868391	3	